Kerin B. Adelson, MD, of the Yale Cancer Center, discusses the major healthcare cost drivers at the end of life—aggressive treatments, emergency room visits, and futile care—and strategies for improving value. (Abstract 3)
Randall F. Holcombe, MD, of the Icahn Mount Sinai School of Medicine, discusses the challenges of delivering quality care in an academic setting at a large hospital.
Allison Kurian, MD, of Stanford University School of Medicine, discusses pressing questions about the clinical utility and value of extended genomic testing and other forms of precision medicine.
Lee N. Newcomer, MD, of the UnitedHealth Group, gives his perspective on how to assess quality in the age of precision medicine.
Lawrence N. Shulman, MD, of the University of Pennsylvania, discusses his paper, which explores lessons learned from analyses of the National Cancer Data Base. (Abstract 173)
Joseph O. Jacobson, MD, of the Dana-Farber Cancer Institute, discusses a session he co-chaired on the thorny questions of how best to improve cancer care.
